IP Library › Granted Patent US 12,351,859
Granted Patent B2
US 12,351,859 · App. 18/192,922 · Granted Jul 8, 2025

Methods for the epigenetic analysis of DNA, particularly cell-free DNA

Inventors: Patrick A. Arensdorf (Palo Alto, CA); Damek Spacek (Redwood City, CA)
Assignee: ClearNote Health, Inc.
C12Q1/6806C07H19/06C07H21/04C07J1/00C12Q1/6827C12Q1/6869C12Q2523/10C12Q2523/115C12Q2537/164
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,351,859
App. No.
18/192,922
Granted
Jul 8, 2025
Kind
B2
Abstract

Methods are provided for the epigenetic analysis of cell-free DNA using organic boranes to convert oxidized 5-methylcytosine residues in the cell-free DNA to dihydrouracil (DHU) residues. Cell-free DNA is contacted with an organic borane selected to successively bring about reduction, deamination, and decarboxylation of oxidized 5-methylcytosine residues such as 5-carboxylcytosine and 5-formylcytosine, resulting in DHU residues in place thereof. Following amplification, the treated cell-free DNA is sequenced, with the DHU residues read as thymine residues. Reaction mixtures, kits and additional methods are also provided, as are related methods for the epigenetic analysis of DNA, including cell-free DNA.

Claims (18)

1. A method for converting an oxidized 5-methylcytosine (5mC) residue selected from 5-carboxylcytosine (5caC) and 5-formylcytosine (5fC) to a dihydrouridine (DHU) residue in cell-free DNA (cfDNA), the method comprising contacting cfDNA containing at least one oxidized 5mC residue selected from 5caC, 5fC, and combinations thereof with pyridine borane.

2. A method for converting a 5-hydroxymethylcytosine (5hmC) residue in a nucleic acid to a DHU residue without affecting 5-methylcytosine (5mC) residues, the method comprising: (a) contacting the nucleic acid with an oxidizing reagent effective to convert at least one 5hmC residue in the nucleic acid to at least one oxidized 5hmC residue selected from 5caC, 5fC, and combinations thereof without affecting 5mC residues; and thereafter

(b) contacting the nucleic acid with pyridine borane to provide a DHU residue in place of the at least one 5caC and/or 5fC.

3. The method of claim 2 , wherein the nucleic acid comprises cfDNA.

4. The method of claim 3 , wherein the oxidizing reagent is a chemical oxidizing reagent.

5. The method of claim 4 , wherein the chemical oxidizing reagent comprises a perruthenate salt.

6. The method of claim 2 , wherein the method is carried out without isolation of any intermediates.

7. The method of claim 2 , wherein the method is carried out in the absence of bisulfite.

8. A method for identifying co-occurrence of 5mC and 5hmC in a single DNA fragment in a cell-free DNA sample, comprising:

(a) tagging 5hmC residues in a fragmented, adapter-ligated cell-free DNA sample with an affinity tag that enables removal of the tagged 5hmC-containing DNA fragments from the sample;

(b) removing the tagged 5hmC-containing DNA fragments from the sample;

(c) oxidizing 5mC in the removed, tagged 5hmC-containing DNA fragments to convert unmodified 5mC residues therein to oxidized 5mC residues selected from 5caC, 5fC, and combinations thereof;

(d) treating the removed fragments with pyridine borane to convert the oxidized 5mC to DHU; and

(e) sequencing the removed fragments and identifying any removed fragments containing DHU as template fragments containing both 5mC and 5hmC.

9. The method of claim 5 , wherein the perruthenate salt comprises potassium perruthenate.

10. The method of claim 5 , wherein the perruthenate salt comprises a tetraalkylammonium perruthenate.

11. The method of claim 4 , wherein the chemical oxidizing reagent comprises a polymer-supported perruthenate.

12. The method of claim 4 , wherein the chemical oxidizing reagent comprises an inorganic peroxo compound.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2024
From: ARENSDORF, PATRICK A.; SPACEK, DAMEK
To: BLUESTAR GENOMICS, INC.
Reel/Frame 068395/0712 →
CHANGE OF NAME Recorded Aug 26, 2024
From: BLUESTAR GENOMICS, INC.
To: CLEARNOTE HEALTH, INC.
Reel/Frame 068776/0580 →
Continuity (3)
Division 16275237 · Feb 13, 2019
Provisional Application 62630798 · Feb 14, 2018
Related Publication 20230235380A1 · Jul 27, 2023
References Cited (26)
US 7582420B2 · Oliphant et al. · 2009 [cited by applicant]
US 8106200B2 · Burkhardt · 2012 [cited by applicant]
US 8741567B2 · He et al. · 2014 [cited by applicant]
US 9267117B2 · Guan et al. · 2016 [cited by applicant]
US 11274335B2 · Arensdorf · 2022 [cited by examiner]
US 11634748B2 · Arensdorf · 2023 [cited by examiner]
US 20170253924A1 · Lu et al. · 2017 [cited by applicant]
US 20200370114A1 · Song et al. · 2020 [cited by applicant]
WO 2014074450A1 · 2014 [cited by applicant]
WO 2015021282A1 · 2015 [cited by applicant]
WO 2017176630A1 · 2017 [cited by applicant]
WO 2019136413A1 · 2019 [cited by applicant]
Screening of Reducing Agents for the PEGylation of Recombinant Human IL-10 Protein J 32 pp. 337-342 Ambrogelly, Alexandre, et al. 2013. [cited by applicant]
Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine Nat Biotechnol. 29(1 ) pp. 68-72 Song, Chun-Xiao, et al. Jan. 2011. [cited by applicant]
Bisulfite-free, base resolution, and quantitative identification of cytosine modifications Keystone Symposia Conference, DNA & RNA Methylation, Ludwig Institute for Cancer Research, University of Oxford pp. 1-23 Song, C… [cited by applicant]
U.S. Appl. No. 62/614,798, filed Jan. 8, 2018 Song, Chunxiao, et al. [cited by applicant]
U.S. Appl. No. 62/660,523, filed Apr. 20, 2018 Song, Chunxiao, et al. [cited by applicant]
U.S. Appl. No. 62/771,409, filed Nov. 26, 2018 Song, Chunxiao, et al. [cited by applicant]
Bisulfite-free direct detection of 5-methylcytosine and 5-hydroxymethylcytosine at base resolution Nature Biotechnology 37 pp. 424-429 Liu, Yibin, et al. Feb. 25, 2019. [cited by applicant]
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MML Partner TET1 Science vol. 324, 930 pp. 930-935 Tahiliani, Mamta, et al. May 15, 2009. [cited by applicant]
A novel method for the efficient and selective identification of 5-hydroxymethylcytosine in genomic DNA Nucleic Acids Research, vol. 39, No. 8 pp. 1-10 Robertson, Adam B., et al. Feb. 7, 2011. [cited by applicant]
Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes Gnome Research, vol. 22; Cold Spring Harbor Laboratory Press pp. 467-477 Nestor, Colm E., et al. Sep. 6, 2016. [cited by applicant]
2-Picoline-borane: A non-toxic reducing agent for oligosaccharida labeling by reductive amination Proteomics, vol. 10 pp. 2330-2336 Ruhaak, L. Renee, et al. Mar. 24, 2010. [cited by applicant]
PCT Search Report and Written Opinion, PCT/US2019/017902 Apr. 11, 2019. [cited by applicant]
Tet-assisted bisulfite sequencing of 5-hydroxymethylcytosine Nature Protocols, vol. 7, No. 12 pp. 2159-2170 Yu, Miao, et al. Nov. 29, 2012. [cited by applicant]
Quantitative Sequencing of 5-Methylcytosine and 5-Hydroxymethylcytosine at Single-base Resolution, Science vol. 336, pp. 934-937, May 18, 2012, Booth et al. [cited by applicant]